Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 16/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 3/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15381004 | 1.00 | CASP1 (0.64) | CASP1ALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL13788325 | 0.90 | ALDH1A1 (0.60) | CASP1ALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL6159279 | 0.88 | CASP1 (0.64) | CASP1CTSL | |
| SCHEMBL1067460 | 0.88 | CASP1 (0.64) | CASP1ALDH1A1ALOX15CTSK | |
| SCHEMBL19695419 | 0.88 | CASP1 (0.64) | CASP1ALDH1A1ALOX15CTSK | |
| SCHEMBL13724740 | 0.88 | CASP1 (0.64) | CASP1ALDH1A1ALOX15CTSK | |
| SCHEMBL8553630 | 0.88 | CASP1 (0.64) | CASP1CTSL | |
| SCHEMBL376886 | 0.88 | CASP1 (0.67) | CASP1 | |
| SCHEMBL554032 | 0.88 | CASP1 (0.67) | CASP1 | |
| SCHEMBL4280669 | 0.88 | CASP1 (0.67) | CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257375-A1 | AZETIDINE DERIVATIVES FOR THE TREATMENT OF INTEGRIN ASSOCIATED DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2023-08-17 | — | — | US | disclosed |
| EP-1501822-B1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARM LTD (GB) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257375-A1 | AZETIDINE DERIVATIVES FOR THE TREATMENT OF INTEGRIN ASSOCIATED DISEASES | ITGA6, ITGA1, ITGA2 | CASP1 3061/4885ALDH1A1 579/4885ALOX15 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.